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ABSTRACT 
The American University in Cairo 
Association of Single Nucleotide Polymorphisms in the CFH, ARMS2 
and HTRA1 genes with risk of developing Age related macular 
degeneration in Egyptian patients 
By: Radwa Ossama Abbas 
Under the supervision of: Prof. Hassan ME Azzazy 
Age related macular degeneration (AMD) is one of the leading causes of blindness in 
the elderly worldwide. Due to earlier clinical observations that AMD concentrates in 
families, a genetic component to the disease has been suggested. Several genetic 
studies have identified areas of association with AMD on chromosomes 1q31 and 
10q26. On chromosome 1q31 the most famous single nucleotide polymorphism 
(SNP) to be linked to AMD was rs1061170 on the complement factor H gene (CFH). 
This SNP was studied in several populations and was found to be highly associated 
with AMD in most Caucasian populations with odds Ratio (OR) reaching 9.79 for CC 
homozygous and 4.36 for CT heterozygous in some cases. However in Japan, China, 
Korea and South Africa no or weak association was found. Other SNPs on 
chromosome 10q26 were also associated with AMD. SNP rs10490924 (Ala69Ser) on 
the age related maculopathy susceptibility 2 gene (ARMS2) was associated with AMD 
in the USA, Germany, China, Turkey and India with OR values reaching 8.61 for 
homozygotes.  On the HTRA1 (HtrA serine peptidase 1) gene rs11200638 was 
associated with AMD in China, India and the USA with OR reaching up to 7.9 for 
individuals homozygous for the risk allele. Due to varying results of association in 
different populations we aimed to examine the association between AMD and SNPs 
on CFH, ARMS2 and HTRA1 in Egyptian patients, a previously unstudied population. 
We recruited 26 individuals diagnosed with AMD and twenty unrelated age matched 
controls. Genotyping was carried out through polymerase chain reaction (PCR) 
followed by allele-specific restriction digestion and direct sequencing for some cases. 
We found all three SNPs to be significantly associated with AMD. For rs1061170 the 
OR for heterozygous TC genotype was 5.5 (95% CI: 1.145-26.412). While for the 
combined TC+CC genotypes the OR was 8 (95% CI: 1.726-37.090). Similarly, for 
rs10490924 the OR for heterozygous TG genotype was 4.667 (95% CI: 1.187-18.352) 
and for the combined TG+TT genotypes it was 7 (95% CI: 1.852-26.461). In HTRA1 
rs11200638 OR for GA genotype was 5 (95% CI: 1.195-20.922) and for combined 
GA+AA genotypes it was 6 (95% CI: 1.456-24.733). We conclude that our study 
results indicate a trend of association between the three polymorphisms studied and 
AMD in agreement with findings in Caucasian populations.  
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CHAPTER 1. INTRODUCTION 
Anatomy of the eye and retina 
The eye is a sensory organ concerned with detecting and converting light energy into 
neuronal signals and transmitting them to the brain. It is composed of seven main 
regions; the cornea, sclera, aqueous humor, vitreous humor, lens, iris and the retina 
(see figure 1). The retina is the photosensitive region of the eye mainly concerned 
with the detection and conversion of light signals. The retina also includes the 
"Choroid" a vascular system controlling up to 95% of the ocular blood flow. The 
cornea is covered with a tear film which acts as a lubricant protecting the eye during 
blinking and is composed of three layers; aqueous, mucoid and lipid 2.  
The retina is made up of a thin layer of neuronal cells covering the back of the 
eye and acting as a part of the central nervous system. Three main types of cells make 
up the retina; photoreceptors (rods and cones), bipolar and ganglion cells. The 
photoreceptors are the part that converts light energy into neuronal signals which are 
passed into bipolar cells which in turn pass them to ganglion cells and out of the eye. 
Other cells present in the retina include amacrine cells, horizontal cells and 
interplexiform neurons which are responsible for modifying signals before they leave 
the eye 2. Blood is supplied to the retina through two routes; the choroid and retinal 
blood vessels. Retinal vessels supply blood to the inner two thirds of the retina while 
the outer one third is avascular and receives nutrients and oxygen from the choroid 3. 
Two main regions span the retina; the peripheral region contains mostly rods, 
occupies most of the retina and is responsible for detecting gross motion 2. The central 
part of the retina is called the "macula" and is responsible for high resolution Visual 
Acuity (VA) and detection of fine details. The macula is made up of cones mainly, 
has a higher ratio of ganglion cells than any other area and covers a small portion of 
the retina 2, 4. At the centre of the macula is the "fovea" which contains no blood 
vessels, any small injury to the fovea leads to loss of vision, while damage at any part 
of the macula leads to loss of central vision (see figure 2) 2, 5.  
In cross section, ten main layers make up the retina, they are (arranged from 
the inside to outside); the inner limiting membrane, nerve fiber layer, ganglion cell 
layer, inner plexiform layer, inner nuclear layer, outer plexiform layer, outer nuclear 
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layer, external limiting membrane, photoreceptor layer and the retinal pigment 
epithelium (RPE) which is closely attached to the Choroid (see figure 3) 2. Separating 
the RPE from the choroid is a semi-permeable membrane called "Bruch's membrane". 
Cells of the RPE, photoreceptors and choriocapillaries are highly interdependent 
physiologically and thus damage to one highly affects the other. Photoreceptors are 
responsible for photo transduction through reisomerization of vitamin A derivative 
(11-cis retinal) upon detection of light photons. The RPE performs several functions 
including; phagocytosis of the outer limits of photoreceptors in balance with their 
synthesis, nutrient transport, cytokine secretion and regeneration of (11-cis) retinal. 
Finally, choriocapillaries are responsible for supplying the RPE and photoreceptors 
with blood 4, 5.  
Age related Macular degeneration (AMD) 
Clinical features and classification 
With ageing the retina undergoes several biochemical and anatomical changes in 
Bruch's membrane. These changes include; collagenous thickening, calcification and 
lipid infiltration. However, during AMD a major histopathological feature is 
displayed, that is the appearance of lipid rich deposits under the RPE known as 
"Drusen". These appear as yellowish lesions in the macula during fundoscopic 
examination and may be classified as small, medium and large or as soft and hard 
depending on the appearance of their margin. Hard drusen have well defined margins, 
while soft drusen have blurred edges as shown in figures 4 and 5 4, 6. According to the 
stage of the disease AMD is classified as early or late. Early AMD involves the 
development of few medium sized drusen and hyperplasia of the RPE, which results 
in little visual impairment and is often asymptomatic. However if symptoms occur 
they include; blurred vision, scotomas and abnormal dark adaptation 4. Late AMD is 
classified into two types; dry AMD/ geographic atrophy (GA) and wet/ neovascular 
AMD (NVAMD). Since AMD involves damage to the macula even the most 
advanced cases of AMD rarely exhibit loss of peripheral vision (see figure 6) 7. 
Dry AMD or geographic atrophy (GA) 
GA develops gradually and usually involves the centre of the fovea leading to loss of 
central vision over the course of months or even years. As expected with AMD, GA 
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involves the development of drusen. However, the main feature leading to loss of 
vision in GA is cell death in the RPE leading to atrophy of the overlying retina and 
underlying RPE (see figure 7) 8, 9. 
Exudative, wet or neovascular AMD (NVAMD) 
This form of AMD involves the development of new pathological choroidal blood 
vessels called Choroidal Neovascularization (CNV). These blood vessels invade the 
sub-RPE or sub-retinal spaces and may leak serous or lipid exudates. This in turn 
hinders supply of nutrients to and removal of wastes from the retina. Clinically they 
appear as greenish gray lesions surrounded by a ring of hyperpigmentation 6, 9. If these 
blood vessels hemorrhage, the release of toxic iron from hemoglobin may lead to 
further damage to the retina7. In CNV loss of vision is sudden and may take place 
over days or weeks4. At its end, CNV may develop into fibrovascular or atrophic 
macular scar and permanent changes to central vision 9. Several types of CNV occur 
including; classic, occult or mixed (which could be either predominantly classic or 
predominantly occult). In fluorescein angiography (FA) early stages of classic CNV 
show hyperfluorescnce with well defined boundaries. Leakage of the dye occurs at 
later stages and the boundaries become blurred. Early phases of occult CNV show 
irregular elevation of the RPE showing ill-defined area of hyperfluorescence followed 
by spotted hyperfluorescence as a result of fibrovascular pigment epithelium 
detachment. Later phases show leakage of fluorescein which may be of an unknown 
source 6, 9. 
Pathophysiology  
AMD shows interplay between various processes including; oxidative damage, 
abnormal lipid metabolism, immune system irregularities, apoptosis and CNV 5. The 
visual cycle involves re-isomerization of trans-retinol into (11-cis) retinal by the RPE 
as shown in figure 9. As mentioned earlier RPE is also responsible for phagocytosis 
of apical photoreceptor outer segments (POS). As well as maintaining the blood-retina 
barrier. With ageing, RPE dysfunction may result in accumulation of visual cycle 
intermediates that may be toxic to photoreceptors. Accumulation of lipo-
proteinaceous granules called "Lipofuscin" may be also involved in the oxidative 
stress component of AMD3, 5. 
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Role of oxidative Stress 
Respiration in the mitochondria involves the release of a number of reactive oxygen 
species (ROS) including superoxide anions O2
-
 and singlet oxygen. With ageing the 
number of ROS released through the mitochondrial walls increases. These ROS then 
attack proteins altering their structures and resulting in loss of function. They also 
attack lipids with unsaturated fatty acids peroxidizing them as shown in figure 10. 
Peroxidized lipids themselves later on act as ROS, attacking proteins and other lipids 
in a "propagation reaction". These peroxidized lipids can be found in lipofuscin 
granules and increase with increased oxygen exposure of the RPE. The eye is 
especially prone to ROS attacks due to several reasons. Photoreceptors contain the 
most unsaturated fatty acids of the body and are prone to photo-oxidative reactions 
due to their constant exposure to light. They also contain high concentrations of 
retinoids in the RPE which are used to capture light and are rich in double bonds. 
Finally, Bruch's membrane is rich in lipids and is exposed to high oxygen flow. Areas 
of hyperpigmentation showing autofluorescence have been noted in CNV, suggesting 
that lipofuscin plays a role in its development. 
Protective mechanisms in the eye against ROS attacks are present at three 
levels; molecular, cellular and large scale tissue protection. Cellular antioxidant 
enzymes include; superoxide dismutase, catalase, glutathione transferase, glutathione 
reductase, and glutathione peroxidase. Vitamins such as C and E and antioxidant 
carotenoids act on the molecular level. Cellular protection involves increased 
activation of transcription factors such as nuclear factor kB (NF-kB) which affects 
gene expression of antioxidant enzymes. At a large scale level, presence of ROS and 
peroxidized lipids results in increased production of vascular endothelial growth 
factor (VEGF) which is involved in the production of vascular endothelial cells 5, 8, 10 
Drusen and drusogenesis 
Drusen are the pathogenic component most highly associated with AMD and appear 
as amorphous deposits that develop extracellularly in the area between the RPE and 
Bruch's membrane. Normally, 95% of the aged population exhibit few small (< 63 
μm) hard drusen. However  when drusen are more numerous or when soft drusen  (≥ 
125–250 μm) develop in the macula, especially if they appear together with pigment 
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irregularities or depigmentation, they are considered a major risk factor for advanced 
AMD especially NVAMD.  
Drusogenesis involves the interplay between various factors and is a complex 
process that takes place over many years as shown in Figure 11. The pathogenic effect 
of drusen is exerted by both their physical action through displacement of the RPE 
and receptors and also through their indirect effect which involves immune activation 
and inflammation. Many immune associated proteins such as dendritic cell processes, 
immunoglobulins, class II antigens, and most importantly components of the 
complement cascade have been found in drusen. The most important of these are 
complement proteins that include; activators and inhibitors, activation specific 
complement fragments, and terminal pathway components such as the membrane 
Attack Complex (MAC). MAC is known to attack both pathogens and host cells and 
tissues including the RPE and photoreceptors. This indicates that local inflammation 
and activation of the complement cascade may play a role in drusogenesis, 
RPE/photoreceptor degeneration, and Bruch’s membrane disruption 3.  
Choroidal neovascularization (CNV) 
Blood vessels that develop during CNV are usually weak, leaky and curled, they 
usually bleed forming dense macular scars that lead to vision loss. Endothelial cells of 
choroidal blood vessels are normally under strict balance between pro-angiogenic 
factors such as VEGF and anti-angiogenic factors such as pigment epithelium derived 
factor (PEDF) and as a result are called "silent". However, during CNV loss of this 
balance occurs either through increased production of pro-angiogenic factors or 
decreased production of anti-angiogenic factors. The causes for this loss of balance 
are numerous and may include retinal hypoxia or ischemia or immune and 
inflammatory response 
3
. 
Epidemiology  
AMD is one of the most common eye diseases that affect the elderly and is estimated 
to affect 50 million people worldwide contributing to about 8.7% of cases of 
blindness worldwide (see figure 12) 11, 12. In the US it was estimated that nearly seven 
million persons suffered from AMD in the year 2007 5. In the early nineties the 
population of the USA included 30 million persons aged 65 or older. Out of this 
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population 150-200'000 persons developed CNV in one or both eyes, with a smaller 
number experiencing loss of vision due to GA 13. 
The epidemiology of AMD was extensively studied in the 90s by three major 
studies; the Beaver Dam study in the USA, the Blue Mountains eye study in Australia 
and the Rotterdam study in the Netherlands. The Beaver Dam Wisconsin study 
included 4926 people aged 43-86 years, who were examined to assess the relationship 
between drusen, RPE abnormalities and macular degeneration with age and sex. The 
study found that 95.5% of the population showed one or more drusen in the macula of 
at least one eye. People above the age of 75 had higher frequencies of the disease 
compared to those 43 to 54 years old 14. In Australia, the Blue Mountains study 
examined 71 patients over 49 years of age to assess the prevalence of early and late 
AMD. Patients were subjected to detailed eye examination and grading of the disease 
according to the Wisconsin age related macular degeneration grading system 
(WARMDGS) to assess the presence and severity of lesions. End stage AMD was 
found in 1.9% of the population with 0% being contributed by people below 55 years 
of age and 18.5% contributed by those 85 or older. Prevalence rates for all lesions 
were lower than those found in the Beaver Dam study 15.  Finally in Rotterdam, 
Netherlands a study was conducted to determine the prevalence of AMD in the 
elderly population. The study population included 6251 patients aged 55 to 98 who 
were examined for the presence of drusen, pigmentary abnormalities and atrophic 
NVAMD. Drusen were found in 40.8% of persons aged 55 to 64 and increased to 
52.6% for people above the age of 85. Drusen, RPE hypopigmentation and increased 
retinal pigment also increased with age. Atrophic or NVAMD were found in 1.7% of 
the population and also increased with age. NVAMD was twice as common as 
atrophic AMD. Overall the disease was found to be less common than in the United 
States 16. 
Results from other ethnic groups show that the prevalence and incidence of 
AMD varies remarkably between different ethnicities. For example; NVAMD is more 
common than GA in Caucasians as reported in; the beaver Dam, Blue Mountains and 
Rotterdam studies. However, GA was found to be more common in Caucasians in 
Iceland and Norway. GA is also more common than NVAMD in other racial groups 
such as the Inuits of Greenland. Recent population based studies have also shown that 
GA was more common in Caucasians than blacks. Data from the National Health and 
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Nutrition Examination Survey III as well as the Los Angeles Latino Eye study and the 
Proyecto VER also showed higher prevalence of NVAMD in whites compared to 
Mexican Americans 17. 
 
Risk factors 
The risk factor most highly associated with AMD is age. Another highly implicated 
risk factor is smoking. Other risk factors include family history and hypertension and 
the minor risk factors; increased C-reactive protein (CRP), increased white blood cell 
count, increased intake of fat and being a female. Most studies found no link between 
elevated lipids or clinical manifestations of atherosclerosis, such as myocardial 
infarction or stroke, with advanced AMD. The Beaver Dam study also found no 
association with hypertension. No relationship with diabetes mellitus was also found. 
A link to cataract surgery has been found and thus it has been recommended that 
ophthalmologists notify their patients of this risk before surgery and follow up with 
them post-operatively. Several factors were found to be protective of AMD including; 
black race, higher intake of fish, nuts and dark green leafy vegetables 4, 8, 17.  
 
Smoking 
Smoking affects several metabolic pathways that have been implicated in the 
pathology of AMD. Smoking lowers levels of the antioxidant carotenoids in the eye 
as well as antioxidants in general in the serum. The Beaver dam, Rotterdam and Blue 
mountain studies have shown that smoking increases odds of CNV with Odds Ratio 
(OR) ranging from 2.5 to 5.6. Follow up studies have also found that incidence of 
AMD increase with the number of packs smoked with risk ratios of 2.0 or larger for 
40-45 packs/year or more 13, 17. 
Alcohol 
An association between alcohol consumption and AMD has been established 
especially for heavy drinkers who consume more than three drinks a day. However, 
study results were not conclusive as most alcohol consumers also smoked and as a 
result separating the effects of alcohol from those of smoking was difficult 18.  
8 
 
Diagnosis of AMD 
Clinically AMD may present as distortion or blurring of vision and scotoma in central 
vision which may be sudden in CNV and more gradual in GA. Patients with bilateral 
GA and unilateral CNV may be asymptomatic. Patients with drusen and mild 
pigmentary changes may have normal visual acuity while late AMD usually results in 
reduced visual acuity in the affected eye. An Amsler grid, which is a grid of vertical 
and horizontal lines, may be used to detect central distortion. Scotomas may be also 
detected using the Amsler grid, these are areas of loss or degradation of VA within a 
normal field. Stereoscopic fundal examination (usually using slit lamp microscopy) 
usually shows drusen, pigmentary, exudative, hemorrhagic or atrophic changes to the 
macula. Fluorescein angiography (FA) is usually used to confirm the presence of 
AMD and may be used to assess the nature of NVAMD 9. FA involves injecting a 
fluorescent dye intravenously which is then imaged using different filters 6. An 
additional diagnostic tool is use of Optical Coherence Tomography (OCT) which 
involves cross sectional imaging across the retina, RPE and choroid. OCT helps in 
assessing presence of pigment epithelial detachments and for patients allergic to 
sodium fluorescein 9.     
Management and Treatment  
Prophylaxis 
Due to the role played by oxidative damage in development of AMD, endogenous 
enzymes and compounds as glutathione help in protecting the retina against oxidative 
damage. The antioxidant effects of vitamins C and E, β-carotenes, flavonoids and 
polyphenol may also help in protection against AMD. Antioxidant enzymes present in 
the RPE require micronutrients as Selenium, Zinc, Manganese and Copper to perform 
their action 19. The age related macular degeneration study (AREDS) investigated the 
use of four nutritional treatments for the prevention of AMD, study groups included 
placebo, zinc, anitoxidants (vit. C, vit. E and beta carotene) and zinc plus 
antioxidants. It was found that zinc plus antioxidants reduced the risk of patient's 
progressing to advanced AMD (OR 0.72) or moderate vision loss (OR 0.73) over a six 
year period. The benefit is greatest for patients with early AMD in one eye and late in 
the other 9.  
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Non-exudative AMD 
No therapy for non-exudative AMD is available to stabilize or reverse disease 
progression. Laser coagulation has been used to remove drusen but its value in 
lowering the progression of AMD is doubtful. Measures that reduce risk of 
developing AMD include lowering or avoiding cigarette consumption. Other factors 
include diet changes since the AREDS study found that vitamin E, beta carotene, 
vitamin C, zinc and copper can reduce the risk of visual loss in patients with moderate 
to severe dry AMD. Also found to reduce the risk are the carotenoids; lutein and 
zeaxanthin which are the only carotenoids concentrated in the macula 7. 
Exudative AMD 
1) Conventional laser treatment (laser photocoagulation therapy) 
Conventional laser treatment was the go-to method for treating CNV before the year 
2000. It involves removal of areas of CNV which may result in improved VA. 
However, this method has been shown to have nearly 54% recurrence rate 5 years 
after treatment. The method also involves exposing all areas of CNV to intense laser 
which usually includes the fovea and leads to loss of fine vision 7, 9, 20.   
2) Photodynamic therapy (PDT) with Verteporfin 
This method approved by the FDA in the year 2000 involves IV injection of 
Verteporfin (Visudyne®, Novartis) a photosensitizing drug, followed by exposing the 
affected area to diode laser (689nm). The photosensitive molecules of Verteporfin 
absorb light energy and release free radicals to oxidize the lipid membranes and 
proteins resulting in disruption of cellular structures, thrombosis and occlusion of 
vasculature in active CNV. This treatment is not effective on minimally classic 
lesions or occult CNV. The treatment course usually involves therapy every 3 months 
for two years (nearly five treatments over two years). Phase three studies have showed 
that PDT reduced risk of severe vision loss by 66% compared to placebo. However, 
only 13% of patients gained vision compared to 7% for placebo, and most treated 
patients still suffered from vision loss even if it was less than expected for the natural 
course of the disease 4, 7, 9.  
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3) Anti-angiogenic drugs    
a. Anti-vascular endothelial growth factor (anti-VEGF) 
Due to the role played by VEGF in the development of new blood vessels anti-
angiogenic drugs have been employed in the treatment of CNV. Two anti-VEGF 
drugs have been FDA approved for treatment of CNV. Pegaptinib sodium (Macugen-
Eyetech Inc.) is an anti-VEGF oligonucleotide (RNA aptamer) conjugated to 
polyethylene glycol; it exerts its action by binding to the major human soluble VEGF 
isoform (VEGF165).  Ranibizumab (Lucentis-Genentech Inc.) is a recombinant anti-
VEGF monoclonal antibody fragment that binds all isoforms of VEGF-A. Another 
anti-VEGF agent used off label for treatment of CNV is Bevacizumab (Avastin-
Genentech Inc.) used originally as anticancer agent for colorectal, lung and breast 
cancer). Bevacizumab is a full length humanized monoclonal antibody against all 
isoforms of VEGF-A. Several cases of blindness resulting from microbial 
contamination of Avastin vials have been reported in the year 201121. Pegaptinib costs 
$995/dose every 6 weeks while Bevacizumab costs $10/dose, and Ranibizumab costs 
$1950/dose 4, 7, 9, 20, 22.  
b. VEGF trap 
A decoy receptor for VEGF, it has higher affinity than naturally occurring receptors. 
It is a recombinant protein with the key ligand-binding sites present in natural 
receptors together with the Fc portion of human IgG. It acts on all members of the 
VEGF family. It is currently in Phase II/III of clinical trials 23.  
c. Tyrosine kinase inhibitors 
VEGF binding to its receptors results in a downstream reaction cascade involving 
tyrosine kinase as shown in figure 13. Activation of this pathway leads to the pro-
angiogenic activity of VEGF with increased cell proliferation and permeability. 
Vatalanib is a multi-VEGF receptor inhibitor that binds the intracellular kinase 
domain of all three VEGF receptors (VEGFR 1-3). It is an oral product and thus 
avoids the commonly employed intravitreal pathway which involves the drug being 
injected directly into the eye. It is currently in phase II/III of clinical trials. 23. 
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d. Pigment epithelium derived factor (PEDF) 
PEDF is a potent anti-angiogenic factor. Adenovirus containing PEDF encoding DNA 
is injected into the vitreal or retinal space. Trials on animals showed regression of 
CNV following therapy 23.   
e. Nicotinica acetylcholine receptor antagonists 
Involvement of a cholinergic pathway in angiogenesis has been recently discovered. 
Thus, pharmacologic inhibition of nicotinic acetylcholine receptor (nAChR) has been 
under investigation with phase I trials showing that mecamylamine (an nAChR 
antagonist) shows reduced CNV lesion size upon intravitreal administration 23. 
f. Small interfering RNA (siRNA) 
Upon entry of double stranded RNA into the cell they are detected as means of viral 
infection and are processed by enzyme dicers into single stranded nucleotides called 
small interfering RNA (siRNA). These strands bind RNA-induced silencing complex 
(RISC) which as a result degrade the complementary messenger RNA (mRNA) 
resulting in reduced VEGF production in the cell. Usually siRNA are directly injected 
into the cell to avoid induction of antiviral defenses through injection of dsRNA. 
Examples of proteins targeted by siRNA therapy in CNV are VEGF and VEGF 
receptors. One example of this therapy is Bevasiranib (Cand5) a siRNA that targets 
VEGF-A mRNA. Since siRNA therapy aims at reducing production of VEGF, it may 
not be effective in reducing already produced VEGF and thus concomitant 
administration of an agent that binds VEGF may show higher efficacy (such as 
combining Bivasiranib and Lucentis) 23.  
4) Steroids 
Include Triamcinolone and Anecortave acetate and act through preventing vascular 
growth by inhibiting proteases necessary for endothelial cell migration 9.  
5) Surgical treatment  
a. Excision of Choroidal neovascular membranes 
12 
 
Excision of Choroidal neovascular membranes involves vitrectomy followed by 
removing CNV by retinotomy incision which could help preserve photoreceptors. 
This is more suitable for occult CNV as the boundaries are not delineated 9. 
b. Retinal pigment epithelial cells transplantation 
Could be exogenous or autologous both methods are showing non-encouraging results 
with high complications 9. 
c. Evacuation of submacular hemorrhage 
Evacuation of submacular hemorrhage involves removing submacular hemorrhage 
secondary to CNV to prevent subretinal fibrosis and permanent vision loss 9. 
d. Macular translocation 
Macular translocation involves relocating the fovea to a neighboring area with healthy 
RPE in patients of subfoveal CNV, it may lead to retinal detachment, increased lens 
opacity and tilted image 9, 20.  
Combination therapy 
Currently under investigation and involves combining anti-VEGF therapy with other 
methods of treatment such as PDT or IV Triamcinolone 9. 
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CHAPTER 2. LITERATURE REVIEW 
Genetics of Age related macular degeneration 
AMD is a complex disease that involves interplay between genetics and the 
environment. The genetic component of AMD has been proven to include not only a 
single gene but to be of a polygenic nature with multiple genes playing a role in the 
development of AMD 24.   
Familial aggregation and Twin studies  
For a long time clinical observations have noted that AMD clusters in families and 
thus a genetic component has been suggested to play a role in developing the 
disease
24
. In the 1990s Silvestri et al conducted a study to examine the level of genetic 
predisposition to AMD and to define a mode of inheritance for the disease. They 
examined 36 AMD patients (both CNV and GA) as well as sex matched controls and 
their immediate families. They found that 20 of the 81 siblings of the patients had 
AMD compared to one of the 78 control siblings. These were statistically significant 
results that supported the involvement of hereditary factors in the etiology of AMD 25. 
The next logical step was conducting familial aggregation studies to figure out if an 
individual had a higher risk of developing AMD if he was related to a patient 24. The 
findings by Seddon et al concluded that first degree relatives of AMD patients 
especially those with CNV had higher prevalence of AMD compared to relatives of 
healthy individuals, thus indicating a genetic component together with the 
environmental component of AMD 26. Klaver et al used data from the Rotterdam 
study using first degree relatives of 87 patients of late AMD and first degree relatives 
of 135 control subjects without AMD. They also found that first degree relatives of 
patients with AMD have increased rate of developing the disease at a relatively young 
age. Their results showed that nearly one fourth of all late AMD is genetically 
determined thus validating the importance of the genetic component of the disease 27. 
Twin studies followed where the balance between genetic and environmental factors 
is assessed through examining a trait in both identical and non-identical twins 24, 28. 
Meyers et al compared the concordance of AMD in monozygotic and dizygotic twins 
who are 40 years or older with AMD between 1986 and 1991. They found that AMD 
was concordant in 100% (25 of 25) monozygotic twins and in five out of 12 (42%) of 
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dizygotic twins. The 100% concordance in monozygotic twins may indicate a strong a 
non-genetic component if repeated in dizygotic twins, however since this is not the 
case a major genetic component is suggested 29.  
Linkage studies and Genome scans 
At this point linkage studies to identify chromosomal regions carrying DNA markers 
that occur at a higher frequency of a certain disease allele in patients compared to 
healthy individuals were conducted. Linkage is measured through measuring the LOD 
score (logarithm of odds) between the marker and the disease. In 1998 a linkage study 
conducted by Klein et al found linkage between AMD and chromosome 1q25-q31 in 
a large family with dry AMD 30. Kenealy et al found linkage between AMD and locus 
10q26 in 70 multiplex families (consisting of 133 affected sibpairs) 31. Genome 
studies followed to identify chromosomal regions associated with AMD. In the year 
2000, Weeks et al genotyped 225 AMD families with 212 affected sibpairs for 386 
markers and found linkage at chromosome 10 32. In 2001 they expanded their study to 
increase the linkage detecting power and included 860 affected individuals from 391 
families including families containing at least two siblings affected with AMD. The 
study confirmed linkage to the locus on 1q31 which was previously reported by Klein 
et al 33. Schick et al in 2003 found a weak signal on chromosome 1 and confirmed 
previously reported linkage to markers on chromosome 12, they also found linkage to 
a locus on chromosome 6 34. Seddon et al also confirmed the results of Klein et al for 
Chromosome 1, Weeks et al for chromosome 10 and Schick et al for Chromosome 6 
35. Genome-wide scan and genetic linkage analysis by Majewski et al linked the 
following loci to AMD; 1q31, 3p13, 4q32, 9q33, and 10q26 36. High resolution 
genome scan by Abecasis et al also confirmed linkage to 1q31 but surprisingly found 
no linkage to the previously reported 10q26 locus 37. While the genome scan by 
Iyengar et al in 2004 showed a major linkage locus on chromosome 15q and a total of 
13 regions on 11 chromosomes (1q31, 2p21, 4p16, 5q34, 9p24, 9q31, 10q26, 12q13, 
12q23, 15q21, 16p12, 18p11, and 20q13). These results Confirmed association with 
previously reported loci including 1q31 and 10q26 38.  
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Association studies 
Complement system 
Association studies were employed to examine if there is an increased presence of a 
certain allele in persons affected by the disease in comparison with the general 
population. In the case of AMD they were used to fine-map regions of significant 
linkage on chromosomal region 1q25-32 24. In the year 2005, association studies 
undertaken by three separate groups were able to establish a relationship between the 
Single Nucleotide Polymorphism (SNP) rs1061170, sequence T1277C, protein 
Y402H on the Complement Factor H gene (CFH) and risk of developing AMD (for 
gene view see figure 14).  
Haines et al genotyped 44 SNPs on Chromosome 1q31 for association in two 
independent data sets (the first with 182 families and the other with 495 AMD cases 
and 185 controls). In both data sets the CFH gene showed the most significant 
association results. They then screened 24 patients and controls for risk associated 
variants in the coding region of CFH, and found a greater presence for rs1061170 in 
cases as compared to controls. The odds ratio for AMD was 2.45 (95% CI: 1.41 to 
4.25) for carriers of one C allele and 3.33 (95% CI: 1.79 to 6.20) for carriers of two C 
alleles. When the analysis was restricted to only neovascular AMD, these odds ratios 
increased to 3.45 (95% CI: 1.72 to 6.92) and 5.57 (95% CI: 2.52 to 12.27), 
respectively 39. Klein et al carried out an association study using 96 cases and 50 
controls from the AREDS study. They tested SNPs for allelic association with the 
disease status and found rs1061170 to be strongly associated with AMD 40. Finally 
Edwards et al carried out an allele association study on case-control studies with a 
discovery sample of 224 cases and 134 controls and a repeat sample of 176 cases and 
68 controls. The most significant association was found for rs1061170 out of 86 SNPs 
genotyped in the Regulation of Complement Activation (RCA) complex and its 
flanking regions. The relative risk for developing AMD for a person carrying at least 
one C allele was 2.7 (95% CI: 1.9 to 3.9) 41. Hageman et al conducted an association 
study for sequence variants in AMD on two independent cohorts of nearly 900 AMD 
patients and 400 controls. The study found association for 8 common CFH SNPs with 
the mis-sense variant at Y402H having a highly significant association. The study was 
also able to identify an at risk haplotype (that includes the Y402H variant) that was 
found in 50% of AMD cases and 29% of controls with OR= 2.46 (95% CI 1.95-
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3.11)42. Further discussion of the complement system and its genetic role in AMD can 
be found below. 
Several other studies testing the association between AMD and the Y402H 
polymorphism on different populations are summarized in table 1. Strong associations 
were detected in the populations of the US, Australia, Brazil, Finland, France, Israel, 
Italy, the Netherlands, Turkey and Russia with OR reaching 9.79 for CC homozygous 
and 4.36 for CT heterozygous 43-56. On the other hand studies in Japan, Korea, South 
Africa and China have found no or weak association between the disease and CFH 
Y402H polymorphism. In Japan three studies concluded that there was no association 
between Y402H and the disease 57-59. In Korea Kim et al found that Y402H was 
marginally associated with NVAMD 60. While in South Africa Ziskind et al found no 
association between Y402H allele and the disease in the Black South African Xhosa 
population 61. In China results were conflicted with Lau et al and Gao et al finding an 
association between Y402H and the disease with OR reaching 4.4 62, 63. On the other 
hand several other studies found no association between this specific SNP and risk of 
developing AMD in Chinese patients 11, 64-66. Ng et al found several other SNPs in the 
CFH to be associated with exudative AMD including; rs3753396, rs3753394, 
rs551397, rs800292, rs2274700, and rs1329428 64. Chen et al also identified strong 
association at the SNPs; rs3753394, rs800292 and rs1329428 but not at rs1061147, 
rs1061170 or rs380390 11. These results show that different ethnic groups and 
backgrounds showed different associations between Y402H and the risk of 
developing AMD.       
 
Chromosome 10q26  
Several association studies were conducted to identify the relationship between AMD 
and two loci on chromosome 10q26 which was previously identified through linkage 
analysis. First of these loci is LOC387715 (later named the age related maculopathy 
susceptibility 2 gene/ARMS2 whose function is yet to be identified (for gene view see 
figure 15). Expression of the protein related to this gene has been shown to be limited 
to the placenta and under normal conditions transcripts from LOC387715 don’t 
appear in the retina and it is likely that its expression is weak. The gene has two exons 
and is transcribed into an 818bp mRNA encoding a 107 amino acid protein that has 
no matches in the public protein or protein motif database, rs10490924 occurs in the 
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coding sequence for this gene 67-69. Significant association between rs10490924 
polymorphism (Ala69Ser) and AMD was found in the USA, Germany, China, Turkey 
and India with OR values reaching 8.61 for homozygous and 3.35 for persons 
heterozygous for the risk allele (see table 2) 45, 54, 56, 65, 68-70. While in Russia the 
association was weak and only detected in cases of CNV 55. 68 
Another locus is the HTRA1 (HtrA serine peptidase 1) which encodes a family 
of heat shock serine proteases which are expressed in mouse retina and human RPE 
gene (for gene view see figure 16). These proteases are responsible for the regulation 
of extracellular matrix proteoglycans which in turn facilitate access of other 
degradative matrix enzymes as collagenases to their substrates. HTRA1 also binds and 
inhibits transforming growth factor β (TGF-β) an important regulator of angiogenesis. 
Altering the levels of HTRA1 could allow degradation of the extracellular matrix thus 
allowing the infiltration of choroidal blood vessels and loss of RPE as characteristic 
of CNV. The rs11200638 polymorphism occurs in the promoter for HTRA1 and is 
nearly 6.1Kb downstream of LOC387715. Some studies have shown that this 
polymorphism is associated with increased levels of HTRA1 mRNA and protein 65, 68, 
71. Studies conducted in China, India and the USA have found significant associations 
between the rs11200638 and risk of developing AMD with OR reaching up to 7.9 for 
individuals homozygous for the risk allele (see table 3) 54, 65, 66, 68, 70, 72          
 
The complement system 
The complement system plays an important role in the interplay between adaptive and 
innate immunity, as well as contributing to physiological homeostasis in general to 
remove damaged, necrotic, and apoptotic cells. The complement system functions to 
eliminate pathogens from the bloodstream by disrupting their membranes through 
pore formation. This system functions through both an antibody-directed fashion (the 
classical pathway) and independent of specific antigenic recognition (the alternative 
pathway) 10, 28, 71, 73. The complement system is composed of several soluble and 
membrane bound factors and is active in intravascular spaces, body fluids and tissues. 
The system is activated by one of four pathways the classical, lectin or alternative 
Pathways (AP) which all converge at the C3 activation step, as well as the intrinsic 
pathway 71. The intrinsic pathway involves cleavage of C3 or C5 by serine proteases 
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associated with coagulation/ fibrinolytic cascades which results in the direct activation 
of the complement pathway. The classical pathway is initiated through interaction 
between antibodies or molecules released by inflammatory processes with pattern 
recognition receptors on CIq. While the lectin pathway is initiated by interaction 
between carbohydrates on microbes and lectin proteins such as mannose binding 
lectin. CIq and mannose binding lectin form complexes with serine proteases (Clr/Cls 
and MASP, respectively), to cleave C4 into its functionally active components C4a 
and C4b. C4b then binds C2 helping its cleavage into active C2a and then binding it 
into the complex C2aC4b which is a C3 convertase. The alternative pathway is a 
spontaneous pathway and thus it provides as quick response to pathogens and cellular 
damage. The alternative pathway forms a different C3 convertase through 
spontaneous hydrolysis of an internal C3 thioester. This forms C3(H2O) a fluid-phase 
version of C3b which binds C3 changing its conformation and facilitating further 
cleavage by factor D into Ba and Bb fragments. C3(H2O) binds with Bb, forming the 
initial alternative pathway convertase C3(H2O) Bb 
71. All pathways meet at the C3 
activation step where C3 convertase cleaves C3 into C3a an anaphylatoxin and C3b. 
C3b then binds factor B to form C3bB which facilitates its cleavage by factor D into 
C3bBb itself a C3 convertase in a step that amplifies C3 activation. C3bBb either 
binds C4b2a of the lectin pathway or C3b of the alternative and classical pathways to 
form C4b2aC3b and C3bC3bBb respectively which both act as C5 convertases. C5 
convertase cleaves C5 into the anaphylatoxin C5a and C5b which undergoes several 
downstream changes to form the membrane attack complex (MAC). MAC is 
responsible for target cell lysis and death through formation of pores in their cell 
membranes 71, 73. Regulation of the alternative pathway occurs through a number of 
structurally similar complement proteins such as the membrane bound CPH, decay 
accelerating factor, membrane cofactor protein, C4-binding protein, and complement 
receptor 1 and the fluid phase complement factor H (CFH). CFH blocks activation of 
C3 into C3b and also aids the Factor1 mediated degradation of C3b (see figure 17) 10, 
28, 71, 73. Abnormal structure or functioning of complement pathway regulators can lead 
to imbalance in the normal homeostasis of the complement system which as a result 
can lead to damage of healthy cells. Since CFH is the only fluid phase regulator its 
aberrant functioning may lead to serious changes in the pathway 71. 
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Complement and AMD 
As mentioned earlier drusen were found through immunohistochemical and 
biochemical studies on eyes of AMD patients to contain a large concentration of 
complement proteins. This is why it was deduced that drusen are a by-product of 
complement pathway related inflammatory response 
71
. 
CFH Y402H 
It has been suggested that the change of positively charged Histidine into an 
uncharged hydrophobic Tyrosine caused by the Y402H SNP results in aberrant 
binding of CFH to the anionic surfaces of retinal capillaries as well as problems with 
binding to C3b leading to problems with the formation of MAC 63, 73. Y402H is 
located at a site on CFH that influences its binding to C-reactive protein (CRP) a 
biomarker for inflammatory response. Patients of AMD show accumulation of CRP in 
the RPE which suggests problems in its binding to CFH 43, 49, 73. 
Other complement SNPs 
SNPs other than the CFH Y402H SNP have been found to be involved in the 
development of AMD. Li et al found stronger association between AMD and 20 other 
SNPs in the CFH with 3 SNPs showing the strongest association namely;  rs2274700 
in exon 10 and the two intronic SNPs, rs1410996 and rs7535263 74. SNPs outside the 
CFH gene include SNPs in CFE, C2, C3 and deletions on CFHRI and CFHRJ genes. 
Since C3 acts as a meeting point for all complement pathways, SNPs in C3 have been 
identified as risk factors for AMD. These include the rs2230199 polymorphism where 
individuals heterozygous for this SNP had OR= 1.7, and homozygotes had OR= 2.6 
10. SNPs on the C2 and CFB genes were shown to be protective of AMD and can to an 
extent counteract the risk alleles on some other genes 44, 71, 75, 76. 
Complement based therapies  
Several potential therapies targeting the complement system are currently under 
investigation with none released into the market yet. These include inhibition of C3 
activation or C3 convertase assembly, promoting C3 convertase decay, promotion of 
factor l-mediated C3B proteolysis, inhibition of C3 and/or C5 convertase activities, 
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inhibition of membrane attack complex assembly by CD5-9, and promoting the 
protective action of CFH 
71
.  
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CHAPTER 3. MATERIALS AND METHODS 
Patients and control individuals 
Two independent groups including AMD patients and non-AMD controls were 
recruited from the retina clinics at the National Eye Research Center in Road el Farag, 
Mansoura University Medical School and The Research Institute Of Ophthalmology 
in Giza over the period from June 2010 till July 2011. IRB approval of the study 
protocol was obtained from the American University in Cairo. A total of 46 
individuals including 26 patients of AMD (25 with CNV and one patient with GA) 
and 20 non-AMD controls participated in the study. The patient group included 9 
females and the control group containing 11 females. All members of both groups 
were above 50 years of age.  Patients were included in the study if they exhibited 
sufficient media clarity for fundus photography and signs of AMD including macular 
lesions in one or both eyes not related to other eye diseases. Patients with diabetic 
retinopathy, ocular trauma, retinal detachment, high myopia and or choroidal or 
retinal dystrophy were excluded from the study. 
Ophthalmic examination  
Members of both groups received standard ophthalmic examination by a retinal 
specialist including visual acuity measurement and slit lamp biomicroscopy. AMD 
patients underwent FA and for some cases OCT was performed to confirm diagnosis. 
Controls were confirmed not to show evidence of AMD in both eyes.  
DNA extraction and genotyping 
Eight milliliters of peripheral venous blood samples were collected into K3EDTA 
blood collection tubes. DNA was extracted from the buffy coat using a commercially 
available blood extraction and purification kit (QIAamp blood mini extraction kit, 
Qiagen, Hilden, Germany) according to the manufacturer's instructions and stored at -
80ºC. Genotyping was carried out through PCR followed by allele-specific restriction 
digestion and direct sequencing. Primer sequences for PCR and sequencing reactions 
are shown in table 4. PCR reactions were slightly adjusted from the method by Xu et 
al and performed using Applied Biosystem's Verity 96 well Thermal cycler 68. PCR 
reaction volume was 25µL including 10μL buffer (including 25mM/L MgCl2, 25μM 
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of each dNTP, 1pmol of each primer and 0.5 units Taq polymerase) as well as 50ng 
genomic DNA. Amplification of HTRA1 involved the addition of 5% dimethyl 
sulfoxide (DMSO) to the reaction mixture. Samples were exposed to denaturing at 
95ºC for 5 minutes followed by 35 cycles of denaturing at 95ºC for 15 seconds, 
annealing at 57ºC for 15 seconds and extension at 72ºC for 45 seconds with the final 
extension extended to 3 minutes. PCR products were resolved on 2% agarose gel 
electrophoresis (Seakem LE Agarose, Lonza, Basel, Switzerland) and visualized using 
Ethidium Bromide and ultraviolet light.  
Restriction digestion and sequencing 
Amplification products were then subjected to restriction enzyme digestion according 
to the manufacturer's instructions (New England Biolabs, Ipswich, MA, USA). 
Fifteen microlitre reaction mixtures were prepared including; 10µL PCR product, 
0.25µL enzyme and 4.75µL 1X enzyme buffer. The enzymes and conditions are 
shown in the table 5 and all digestions were conducted for 3 hours. Products were 
resolved on 2% agarose gel electrophoresis (Seakem LE Agarose, Lonza) and 
visualized using Ethidium Bromide and ultraviolet light. Genotypes were determined 
using restriction patterns and were further confirmed by direct sequencing. 
Sequencing was conducted using forward and reverse primers and combined Sanger 
and Roche 454 technologies on ABI 3730xl DNA sequencer.  Sequencing results 
were viewed using Bioedit sequence Alignment editor (Ibis Biosciences, Carlsbad, 
CA, USA). Alignment and identification of SNPs was done using Serial Cloner 2.1 
software (Serial basics, www.serialbasic.com), sequences for genes and SNPs were 
obtained from the NCBI database 77.   
Statistical analysis of data 
Numerical data was examined using the student t test. Hardy Weinberg Equilibrium 
(HWE) χ2 values were calculated to identify genotyping errors using the formula 
(p
2
) + (2pq) + (q
2
) = 1.  Linkage Disequilibrium (D') values were calculated using 
Haploview software version 4.2. Genotype and allele frequencies were compared 
using χ2  test, Odds Ratio (OR) and 95% Confidence intervals (95% CI)  were 
calculated using calculators available on the website of the Institute of Human 
Genetics using logistic regression analysis 78. P value below 0.05 was considered 
statistically significant. 
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CHAPTER 4. RESULTS 
A total of 26 individuals diagnosed with AMD were recruited for this study. 25 cases 
suffered from CNV and only one case suffered from GA. Twenty unrelated, ethnically 
matched controls were recruited. Characteristics of the study population are shown in 
table 6. Mean age of cases was 65± 8 versus 60 ± 8 for controls (p= 0.079 using 
student t-test). Percentage of males in cases was 65.3% and for controls 45% 
(p=0.279 χ2 test). Genotypes were determined successfully using RFLP and 
sequencing for confirmation for 20 patients and 15 controls in rs1061170 (CFH), 24 
patients and 20 controls in rs10490924 (ARMS2) and 24 patients and 15 controls for 
rs11200638 (HTRA1). RFLP Band size and distribution are shown in the table 7, a 
sample of RFLP, alignment and sequencing results are shown in figures 18-32. 
Genotype frequencies were in Hardy Weinberg Equilibrium as shown in tables 8-10. 
CFH rs1061170 was significantly associated with AMD with the frequency of 
the risk C allele being 0.53 in cases and 0.17 in controls (p< 0.005, χ2 test). Genotype 
distributions were significantly different between the AMD and control groups 
(p<0.05, χ2 test). Compared to the wild type TT genotype the OR for heterozygous 
TC genotype was 5.5 (95% CI: 1.145-26.412). The OR for the CC homozygous 
genotype was not calculated as this genotype was not detected in the control group. 
For the combined TC+CC genotypes the OR was 8 (95% CI: 1.726-37.090) as shown 
in table 8. 
Similarly, ARMS2 rs10490924 was significantly associated. The risk allele T 
was found at a frequency of 0.5 in the AMD and 0.15 in control populations (p< 
0.005, χ2 test). Genotype distributions were significantly different between the AMD 
and control groups (p<0.05, χ2 test). Compared to the wild type GG genotype the OR 
for heterozygous TG genotype was 4.667 (95% CI: 1.187-18.352). The OR for the TT 
homozygous genotype was not calculated as well since it was not detected in the 
control group. However the OR for the combined TG+TT genotypes was 7 (95% CI: 
1.852-26.461) as shown in table 9. 
In HTRA1 the rs11200638 was found to be significantly associated with AMD, 
with the risk allele A found at a frequency of 0.44 in patients and 0.17 in controls (p< 
0.05, χ2 test). Genotype distributions were significantly different between the AMD 
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and control groups (p<0.05, χ2 test). Compared to the wild type GG genotype the OR 
for heterozygous AG genotype was 5 (95% CI: 1.195-20.922). The OR for the AA 
homozygous genotype was not calculated due to its absence in the control group. 
While the OR for the combined AG+AA genotypes was 6 (95% CI: 1.456-24.733) as 
shown in table 10. 
Combinations of genotypes between rs10490924 and rs11200638 are shown in 
table 11. Carriers of the GT+AG genotype combination had an OR of 4.583 (95% 
C.I= 0.995-21.119) when compared to carriers of the wild type genotype combination 
(GG+GG) as shown in table 12. The two SNPs were found to be in high linkage 
disequilibrium with D'= 0.899, LOD= 5.22 and r
2
= 0.737 in cases and D'=1, 
LOD=2.83 and r
2
= 0.769 in controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
25 
 
CHAPTER 5. DISCUSSION 
AMD is a widespread eye disease that has been implicated as a major cause of 
worldwide blindness especially in the elderly. Clinically, it had been noted for a long 
period of time that AMD clusters in families, indicating a genetic component to 
AMD. This was followed by extensive genetic studies that were able to associate 
several polymorphisms with risk of developing AMD. Of the highest importance are 
complement system polymorphisms including the most famous rs1061170 in the CFH 
(Y402H), as well as other SNPs in the CFH such as rs2274700, rs1410996 and 
rs7535263. Other SNPs in the complement outside the CFH gene include SNPs in 
CFE, C2, C3 and deletions on CFHRI and CFHRJ genes. Outside the complement 
system and on chromosome 10q26 two other SNPs were identified. One is 
rs10490924 on the coding sequence of the ARMS2 gene whose function is yet to be 
identified. The other is rs11200638 which occurs on the promoter for HTRA1 gene 
which encodes a family of heat shock serine proteases. However, during the 
conduction of association studies it became clear that a certain SNP associated with 
risk of AMD in one population is not necessarily associated in another. This case is 
strongly exhibited for the most famous of SNPs CFH Y402H which showed strong 
associations with populations in the US, Australia, Brazil, Finland, France, Israel, 
Italy, the Netherlands and Russia. While no association was found in Japan and South 
Africa and weak or conflicting results were reported in Korea and China. 
We attempted to study the association between AMD and three major SNPs 
that have been previously associated with AMD namely; rs1061170 in the CFH gene, 
rs10490924 on ARMS2 and rs11200638 on HTRA1. The study was conducted on an 
Egyptian population a previously unstudied and ethnically distinct group. We found 
that the association between rs1061170 and AMD was significant with the frequency 
of the risk C allele being 0.53 in cases compared to 0.17 in controls (p< 0.005, χ2 
test). The OR for the heterozygous TC genotype was 5.5 (95% CI: 1.145-26.412) 
compared to the wild type TT genotype. Also the OR for the combined TC+CC 
genotypes the OR was 8 (95% CI: 1.726-37.090). Similarly, rs10490924 was 
significantly associated with the risk T allele found at a frequency of 0.5 in patients 
compared to 0.15 in controls (p< 0.005, χ2 test). OR for the heterozygous TG 
genotype was 4.667 (95% CI: 1.187-18.352) and OR for the combined TG+TT 
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genotypes 7 (95% CI: 1.852-26.461). Finally rs11200638 was found to be 
significantly associated with AMD, with the risk allele A found at a frequency of 0.44 
in patients and 0.17 in controls (p< 0.05, χ2 test). Heterozygous AG genotype had an 
OR of 5 (95% CI: 1.195-20.922) while the AG+AA genotypes had an OR of 6 (95% 
CI: 1.456-24.733). Even though our study sample was small it was able to indicate 
significant association between the polymorphisms studied and AMD.  These results 
agree with findings in Caucasian populations which exhibited ORs reaching 4.3 for 
CT in rs1061170, 3.3 for TG in rs10490924 and 1.86 for AG on rs11200638 (see 
tables 1-3) 45, 50, 65. The study found that the HTRA1 and ARMS2 genes are in high 
linkage disequilibrium in our patient group which is in agreement with findings in 
previous populations 46, 68.  
Obviously the main drive behind AMD genetic research is to be able to 
develop a genetic diagnostic test or platform that allows identification of patients that 
are at risk of developing the disease.  Recent research indicates that identifying 
genetic risk may be of benefit to patients as it may affect disease progression, 
treatment outcome and lifestyle decisions. The interplay between environment and 
genetics in developing AMD has been under scrutiny lately. One of the environmental 
factors that have been strongly linked to AMD is smoking. This is why several studies 
have been conducted to find if the combination of smoking and carrying genetic risk 
factors leads to a higher OR than each factor alone. Seddon et al found that for 
individuals with wet or dry AMD the CC genotype in rs1061170 in CFH conferred 
OR of 10.2 when combined with smoking 79. Baird et al found OR of 2.39 for 
individuals with the CC genotype who were smokers 80. Chu et al found that risk for 
another non coding SNP in CFH rs1410996 was also modified by smoking 81. These 
findings are of great importance since they indicate that being a smoker and carrying 
genetic risk factors increases risk of developing AMD significantly. As a result if a 
person is identified as a carrier of risk genes a change in lifestyle and stopping 
smoking may result in reduced possibility of developing AMD. 
Another benefit of genetic testing for AMD that has been under study with 
mixed results is the effect of SNPs associated with AMD and disease severity. Seddon 
et al found that both the CFH Y402H and ARMS2 polymorphisms were 
independently associated with disease progression into late AMD 82. They also found 
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that the presence of both polymorphisms, BMI> 25 and smoking increased risk of 
progression 19 folds. Francis et al found similar association between CFH and 
development of CNV or GA 72. Other studies were not able to confirm this 
relationship and found no link between SNPs and disease progression 52, 83, 84. Other 
studies found an association between genetic variants and the type of neovascular 
lesions in patients. Brantley et al found significant association between the C allele in 
rs1061170 with predominantly classic lesions 85. Wegsheider et al also found that the 
CC genotype was more commonly present in predominantly classic lesions without 
occult CNV rather than other types of  CNV 86.    
Studies were also conducted to indicate whether genetic changes affect 
response to therapy whether through PDT, Bevacizumab, Ranibizumab or 
antioxidants and zinc. Studies on PDT showed mixed results with Brantley et al 
finding that rs1061170 TT genotypes showed lower improvement in Visual Acuity 
(VA) post PDT treatment when compared to CT or CC genotypes 87. While on the 
other hand, Goverdhan et al found an association between CC genotype and both the 
likelihood of resorting to PDT as well as VA outcome following PDT 88. Others such 
as Feng et al and Seitsonen et al showed that genotypes don’t affect PDT outcome 89, 
90.  Brantley et al also examined the effect of polymorphisms on response to 
Bevacizumab injections and found that CC genotypes did worse with therapy than TT 
and TC genotypes 91. Klein et al found that CC genotypes were more likely to 
progress into advanced AMD after antioxidant and zinc supplementation than other 
genotypes 92. While examining the effects of genotypes on Ranibizumab treatment, 
Lee et al found that genotypes didn’t affect significantly VA post treatment. However 
they affected the number of injections over a 9 months period with CC genotypes 
showing higher risk of requiring extra injections 93.  
For genetic testing to be carried out, it has become apparent that use of a 
single SNP is not specific since differences in genotypes between patients and 
controls may be marginal. Also since studies show that the association varies greatly 
between different ethnic groups 94. This is why use of a panel of SNPs has been 
suggested. Maller et al investigated the association between five CFH variants, 
LOC387715, and C2IFB genes and risk of developing AMD in a large case-control 
study. They found that persons homozygous for all risk variants had a 285-fold 
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greater risk than the lowest risk group 44. However Depspriet et al argued that these 
results are not accurate and proposed that studies need to be repeated in populations 
representative for the settings in which the genetic testing will be applied. They also 
proposed that the discriminative accuracy of testing these SNPs for the prediction of 
end-stage AMD is 80%. This value is considerably high when taking into account that 
the discriminative accuracy of high serum cholesterol for the prediction of 
cardiovascular disease is 77% 95. 
Recently labs that offer genetic testing for factors associated with risk of AMD 
development are starting to emerge in various countries. Using the Gene tests website, 
an NIH related website that allows for searching for Independent laboratories 
conducting genetic testing for a certain disease 96, several independent laboratories 
(mostly university related) were found to carry out genetic testing for AMD as shown 
in table 13 97. For example, the Bay area genetic laboratory offers targeted mutational 
analysis for CFH haplotype groups, C3, ARMS2, mitochondrial A4917G and adjusts 
results for smoking using the Macula risk test® 98. The Molecular Genetics lab in 
Bayern Germany offers targeted mutational analysis for CFH Y402H and HTRA1 
using RFLP 99. Similarly, the Molecular Diagnostics Laboratory at Duke University 
uses RFLP to conduct targeted mutational analysis for CFH Y402H and ARMS2 
genes 100. And finally, the Laboratory of Human Genetics in Warsaw Poland works 
only on the Y402H CFH SNP 101. Commercially available or soon to be available 
genetic tests include the Macula risk® tests for SNPs rs1061170 in CFH, rs2230199 
in C3, rs10490924 in ARMS2 and A4917G in the ND2 gene as well adjusting for 
smoking. The predictive value of this test was found to be 83% in a large, 
independent, prospective clinical trial 102. Also, the AMD risk assessment test by 
Asperbio analyses 3 SNPs associated with high risk in CFH and ARMS2, as well as 3 
SNPs associated with lower risk in CFB and C2 103. Recently, Optherion based in 
Connecticut, USA has completed an exclusive worldwide licensing agreement with 
Sequenom, Inc. Under which Sequenom’s labs will develop and commercialize 
diagnostic tests for AMD 104, 105. Sequenom developed the RetnaGene™ AMD test for 
nine SNPs in; the regulators of complement activation (RCA) locus including, CFH, 
complement factor H-related 4 (CFHR4), complement factor H-related 5 (CFHR5) 
and coagulation factor XIII B subunit (F13B) genes; as well as SNPs in complement 
component 2 (C2), complement factor B (CFB), complement component 3 (C3) and 
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ARMS2 genes. The test focuses only on genetic markers only since they remain static 
throughout life and thus no variable factors are introduced which may affect accuracy. 
Clinical validation of the test showed that the test yielded 82% sensitivity and 63% 
specificity 106, 107.   
Genetic studies on AMD are not focused solely on developing diagnostic tests. 
Therapeutic agents derived from knowledge about the genetics of AMD are currently 
under investigation. Using findings implicating errors in the alternative complement 
pathway in development of AMD, Rohrer et al examined the therapeutic use of novel 
recombinant Factor H to inhibit the AP. They found that specific inhibition reduced 
angiogenesis in mouse CNV 108. Tortajada et al examined the protective role conferred 
by the Factor H- Ile61 variant through ELISA based methods and found that this 
variant binds more efficiently to C3b and competes better in proconvertase formation. 
They also showed through functional analysis that this variant had greater cofactor 
activity for the factor I-mediated cleavage of fluid phase and surface bound C3b 109. 
To identify the role played by the ARMS2 gene in AMD Chen et al expressed a 
recombinant protein encoded by the gene in E.coli. This approach would allow 
identification or isolation of an antibody against this protein, which allows 
identification of any natural protein encoded by this gene in human cells 110.  
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CHAPTER 6. CONCLUSION AND RECOMMENDATIONS 
We conclude that our data demonstrates significant association between AMD and 
rs1061170 on CFH, rs10490924 on ARMS2 and rs11200638 on HTRA1 in Egyptian 
patients. Frequencies of the risk alleles were 0.53 in cases compared to 0.17 in 
controls, 0.5 in patients compared to 0.15 in controls and of 0.44 in patients and 0.17 
in controls for rs1061170, rs10490924 and rs11200638 respectively. The ORs for 
carriers of one risk allele compared to homozygous wild type were 5.5 (95% CI: 
1.145-26.412), 4.667 (95% CI: 1.187-18.352) and 5 (95% CI: 1.195-20.922) for 
rs1061170, rs10490924 and rs11200638 respectively. These findings are the first for 
the Egyptian population an ethnically distinct group. Findings are in agreement with 
findings in Caucasian populations which exhibited ORs reaching 4.3 for CT in 
rs1061170, 3.3 for TG in rs10490924 and 1.86 for AG on rs11200638. The utility of 
genetic testing for AMD has been under an intense debate. Some physicians believe 
that due to the uncertain nature of the role played by genetics in AMD, genetic testing 
may serve no purpose but to increase patients' worries. There are also concerns that if 
information about the patients' risk of developing the disease becomes publicly 
available it could lead to problems in obtaining medical insurance. However, recent 
research indicates that  identifying genetic risk may be of benefit to patients as it may 
affect disease progression, treatment outcome and lifestyle decisions. To examine 
this, studies on the effect of genetic risk factors on disease progression, treatment 
outcome and the interplay between genetic factors and smoking should be conducted 
on Egyptian patients. Expanding the study to include a more diverse sample including 
patients and controls from various parts of Egypt would also add to our understanding 
of the genetics of AMD. Finally, association with other complement SNPs should be 
examined. These include; rs1410996 and rs7535263, SNPs on CFE, C2, C3 and 
deletions on CFHRI and CFHRJ genes, as well as protective SNPs on the C2 and 
CFB genes.  
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CHAPTER 8. LIST OF FIGURES 
 
Figure 1. Structure of the eye. The figure shows the seven main regions of the 
eye; the cornea, sclera, aqueous humor, vitreous humor, lens, iris and the 
retina111.  
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Figure 2. Normal retina with the macula encircled. The macula is the central 
region of the retina and is responsible for high resolution visual activity and 
detection of fine details4. 
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Figure 3. The ten layers of the retina. These are; the inner limiting membrane, 
nerve fiber layer, ganglion cell layer, inner plexiform layer, inner nuclear layer, 
outer plexiform layer, outer nuclear layer, external limiting membrane, 
photoreceptor layer and the retinal pigment epithelium (RPE)112. 
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Figure 4. Retina showing soft drusen113. 
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Figure 5. Retina showing hard drusen113. 
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Figure 6. Loss of vision in AMD. Damage to the macula occurs and thus even the 
most extreme cases of AMD rarely exhibit loss of peripheral vision114. 
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Figure 7. Geographic atrophy.  This is an advanced form of AMD that involves 
RPE cell death resulting in atrophy of the overlying retina and underlying 
RPE115. 
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Figure 8. Choroidal neovascularization. This is an advanced stage of AMD which 
develops in NVAMD and involves growth of pathological blood vessels116. 
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Figure 9: The visual cycle. Showing reisomeration of trans-retinol into 11-cis-
retinal by the RPE
117 
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Figure 10: Oxidative stress and the role played by antioxidant enzymes and 
vitamins118. 
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Figure 11. Schematic diagram of drusogenesis. This is a complex process that 
occurs over the years and is affected by several factors including; genetic 
predisposition, environment and diet and functional and metabolic age related 
changes (modified from3). 
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Figure 12. Worldwide causes of blindness according to the World Health 
Organization. AMD contributes to 8.7% of worldwide blindness119. 
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Figure 13: Interaction of VEGF with VEGF receptors. This interaction triggers 
an intracellular tyrosine kinase reaction (modified from 1
20
). 
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Figure 14. Gene view of rs1061170. This SNP is on Chromosome 1q31 leading to allele change C→T with amino acid change H→Y at 
position 402 of the CFH protein77. 
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Figure 15. Gene view of rs10490924. This SNP is on Chromosome 10q26 leading to allele change G→T with amino acid change A→S at 
position 69 of the ARMS2 protein77. 
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Figure 16. Gene view of rs11200638. This SNP is Chromosome 10q26 leading to allele change A→T on the HTRA1 gene77.
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Figure 17. The complement pathway. CFH regulates complement through 
blocking activation of C3 into C3b and also aiding Factor1 mediated degradation 
of C3b (figure modified from71).  
59 
 
 
Figure 18. RFLP for CFH rs1061170. Digestion using Tsp509I shows 241bp band 
for homozygous CC, 181bp band + 60bp band for homozygous TT and 241bp 
+181bp + 60bp bands for heterozygous TC. Lanes 1 and 2 are TT, lanes 3,4 and 
5 are TC and lane 6 is CC.   
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Figure 19. Sequencing of CFH rs1061170 CC genotype using backward primer. 
The CC genotype shows one black peak. C, A, T and G show Blue, green, red 
and black peaks respectively.  
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Figure 20. Sequencing of CFH rs1061170 TT genotype using backward primer. 
The TT genotype shows one green peak. C, A, T and G show Blue, green, red 
and black peaks respectively. 
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Figure 21. Sequencing of CFH rs1061170 TC genotype using backward primer. 
The TC genotype shows both black and green peaks. C, A, T and G show Blue, 
green, red and black peaks respectively. 
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Figure 22. Alignment results for CFH gene. a) shows results for TC genotype, b) 
for CC Genotype and c) for TT Genotype, to differentiate between homozygous 
and heterozygous genotypes we refer to the sequencing figures. 
64 
 
 
Figure 23. RFLP for ARMS2 rs10490924. Digestion using PvuII shows 449bp 
band for Homozygous TT, 259bp band + 190bp band for Homozygous GG and 
449bp +259bp + 190bp bands for heterozygous TG. Lanes 1, 3 and 6 show TT, 
lanes 2 and 5 show TG and lane 4 shows GG. 
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Figure 24. Sequencing of ARMS2 rs10490924 TG genotype using forward 
primer. TG genotype shows both black and red peaks. C, A, T and G show Blue, 
green, red and black peaks respectively. 
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Figure 25. Sequencing of ARMS2 rs10490924 GG genotype using forward 
primer. The GG genotype shows one black peak. C, A, T and G show Blue, 
green, red and black peaks respectively. 
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Figure 26. Sequencing of ARMS2 rs10490924 TT genotype using forward 
primer. The TT genotype shows one red peak. C, A, T and G show Blue, green, 
red and black peaks respectively. 
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Figure 27. Alignment results for ARMS2 gene. a) shows results for TG genotype, 
b) for GG Genotype and c) for TT Genotype , to differentiate between 
homozygous and heterozygous genotypes we refer to the sequencing figures. 
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Figure 28. RFLP for rs11200638 in HTRA1. Digestion using Eag I shows 385bp 
band for Homozygous AA, 246bp band + 139bp band for Homozygous GG and 
385bp +246bp + 139bp bands for heterozygous AG. Lane 1 is AG, Lane 2 is GG, 
lane 3 is a smear, lane 4 there was no amplification and lane 5 is AA.   
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Figure 29. Sequencing of HTRA1 rs11200638 AG genotype using forward 
primer.  The AG genotype shows both black and green peaks. C, A, T and G 
show Blue, green, red and black peaks respectively. 
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Figure 30. Sequencing of HTRA1 rs11200638 GG genotype using forward 
primer. The GG genotype shows one black peak. C, A, T and G show Blue, 
green, red and black peaks respectively. 
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Figure 31. Sequencing of HTRA1 rs11200638 AA genotype using forward 
primer. The AA genotype shows one green peak. C, A, T and G show Blue, 
green, red and black peaks respectively. 
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Figure 32. Alignment results for HTRA1 gene. a) shows results for AG genotype, 
b) for GG Genotype and c) for AA Genotype, to differentiate between 
homozygous and heterozygous genotypes we refer to the sequencing figures. 
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CHAPTER 9. LIST OF TABLES 
Table 1: Association studies between AMD and CFH rs1061170 polymorphism 
CFH (rs1061170) 
Study/ year Country/ 
Patients/ 
Controls 
Genotyping 
method 
Results  Conclusions 
Zareparsi et al 
2005 50 
USA/616/275 Not specified OR  
TC= 4.36 (95% CI 3.13–6.08) 
CC= 5.52 (95% CI 3.54–8.59). 
 
Y402H polymorphism 
significantly associated with AMD  
Schaumberg et 
al 2006 
43 
USA/111/401  Not specified OR  
TC=1.46 (95% CI: 1.05–2.04) 
CC=2.13 (95% CI: 1.10–4.16)  
Y402H polymorphism 
significantly associated with AMD  
Maller et al 
2006 44  
USA/ 1238 
NVAMD/ 934  
Illumina 
BeadArray  
TC= 2.7-fold increased risk for AMD 
CC= 7.6-fold increased risk 
Y402H polymorphism 
significantly associated with AMD  
Francis et al 
2007 72 
USA/ 333 
advanced AMD 
(108 GA, 205 
PCR followed 
by TGCE or 
direct 
OR= 2.399 (95% CI; 1.768, 3.256) Y402H polymorphism 
significantly associated with AMD 
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CNV)/ 171  sequencing 
Pulido et al 
2007 45  
USA/ 89 NVAMD/ 
230 
PCR-RFLP OR  
TC= 1.16 (95% CI 0.64 to 2.09). 
CC= 4.97 (95% CI 2.52 to 9.79  
Y402H polymorphism 
significantly associated with AMD  
Baird et al 2006 
53 
Australia/ 236/ 144  MALDI-TOF 
validated 
through 
sequencing 
OR  
TC= 1.86 (95%CI= 1.1-3.16) 
CC= 9.26, (95% CI= 4.52-18.98) 
 Individuals with at least one copy 
of the C allele showed increased 
risk of AMD 
Teixeira et al 
2010 49 
Brazil/ 119/ 152  PCR 
sequencing 
TC= increased risk by 1.36-folds  
CC= increased the risk by 4.63-folds 
The Y402H polymorphism is a 
risk factor for developing AMD in 
the Brazilian population  
Lau et al 2006  
63 
China/ 163 
NVAMD/ 232  
PCR-RFLP 
and verified 
through 
sequencing 
C allele OR= 4.4 (95% CI= 2.3– 8.5; P < 
0.00001). 
Y402H polymorphism 
significantly associated with AMD  
Gao et al 2010 62 China/ 208/ 140 PCR-RFLP OR= 2.29 (95% confidence interval, 1.06-4.95). Association of Y402H with AMD 
though to a lower extent than in 
the white population 
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Chen et al 2006 
11 
China/ 163  
NVAMD/ 244 
Taqman assay Significant association at rs3753394, rs800292 
and rs1329428  
but not at rs1061147, rs1061170 or rs380390 
Three SNPs of the CFH gene, 
rs1329428 and rs800292 (I62V) 
and for the first time rs3753394 
increased risk for exudative AMD 
Y402H not associated with AMD  
Ng et al 2008 
64  
Hong kong 
(Chinese)/ 163 
NVAMD/ 155 
Sequencing Significant association at rs3753396 (novel), 
rs3753394, rs551397, rs800292, rs2274700, and 
rs1329428 (previously reported).  
CFH related to susceptibility to 
AMD 
Xu et al 2008 
68 
China/ 121  
NVAMD/ 132  
PCR-RFLP 
and 
sequencing 
Y402H was not associated with exudative AMD. 
Frequencies for the risk C allele were 10.3% in 
AMD cases and 8.0% in controls (p=0.353). No 
significant difference between the CFH 
genotypes in AMD group and control group 
(p=0.496). 
 
Y402H not associated with AMD 
Yang et al 2010 
66 
China (Han 
Chinese)/109 
NVAMD/ 150 
PCR-RFLP CFH rs800292 significantly associated with a 
reduced risk for exudative AMD.  
CFH Y402H had similar allele and genotype 
frequencies in the case and control groups 
Y402H not associated with AMD.  
rs800292 (CFH V62I) highly 
associated with reduced risk of 
AMD 
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(p>0.05). 
Ziskind et al 
2008 
61 
Black South 
African Xhosa 
population/16 
(early AMD)/98 
PCR-RFLP C allele frequency in AMD = 53.1%, in 
controls= 41.8%. CC frequency in AMD= 31%, 
in controls= 13.3%  
No association between Y402H 
allele and the disease 
 
Okamoto 2006  
59 
Japan/ 96 
NVAMD/ 89  
Sequencing Using the four SNPs reported by Hageman et al. 
five haplotype blocks were identified. Haplotype 
5, which contains Y402H was found at a 
frequency of 4% for both controls and AMD 
cases  
No association between Y402H 
allele and the disease 
Gotoh et al 2006 
58 
Japan/ 146 
NVAMD/ 105  
Sequencing The frequency of the C allele of rs1061170 is as 
low as 0.04 in Japanese. 
No association between Y402H 
allele and the disease 
Fuse et al 2006 
57 
Japan/ 80 dry 
AMD/ 196  
Sequencing  The frequencies of Y402H were not significantly 
higher in the AMD group than in the control 
group 
No association between Y402H 
and the disease 
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Seitsonen et al 
2006 46 
Finland/ 181 
familial cases, 154 
sporadic cases/ 105 
non-AMD, 350 
blood donors 
Sequencing combined analysis of familial and sporadic AMD 
cases  
CC showed relative risk= 5.31 (95% CI:3.35-
8.40)  compared to blood donor controls  
= 9.79 (95% CI: 4.76-20.1) compared to non-
AMD controls  
TC risk =2.34 (95% CI:1.54-3.57) compared to 
blood donor controls  
= 2.51 (95% CI: 1.46-4.31) compared to non-
AMD controls 
 
Y402H significantly associated 
with AMD  
Souied et al 
2005 47 
France/ 141 
NVAMD (81 
familial and 60  
sporadic cases)/ 91  
Sequencing  OR  
TC =3.0 (CI 95% 1.6-5.6). 
CC= 6.8 (CI 95% 3.0-15.2)   
After adjustment for age and sex (p<0.0001): OR  
TC=3.0 (CI 95% 1.6-5.6) 
 CC=6.9 (CI 95% 3.1-15.6).     
Y402H associated with NVAMD 
Kim et al 2008  
60 
Korea/ 114 
NVAMD/ 187  
Sequencing  The difference between the frequencies of 
Y402H in cases and controls was not statistically 
Y402H marginally associated with 
NVAMD 
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significant (P =0.071). Other SNPs (-275C>T, 
I62V, and IVS15) were found to be associated 
with an elevated risk of exudative AMD. 
Chowers et al 
2008 52 
Israel/ 240 
NVAMD/ 118 
MALDI-TOF OR 
TC=2.1 (95% CI=1.3 −3.4) 
CC= 3.4 (95% CI= 1.7–6.8).  
Combined OR= 2.4 (95% CI 1.5–3.8, p=0.0005)  
Y402H associated with NVAMD 
Simonelli et al 
2006 48 
Italy/ 104/ 131 Taqman Assay OR CC= 3.9 (95% CI: 1.9 to 8.2  Y402H associated with AMD 
Despriet et al 
2006 51 
Netherlands Taqman Assay OR CC increased in an allele-dose manner;  
= 2.00 (95% CI 1.56-2.55) for stage 2 AMD,  
= 4.58 (95% CI, 2.82-7.44) for stage 3 AMD, 
=11.02 (95% CI, 6.82-11.81) for stage 4 (late, 
vision threatening)  
 
Y402H associated with AMD 
Fisher et al 2007 
55 
 
Russia/ 155/ 151 Sequencing  OR  
TC=2.01 (95% CI 1.14 to 3.56) 
CC=2.71 (95% CI 1.25 to 5.90) 
Y402H associated with AMD (at a 
lower level than western 
population) 
Soysal et al Turkey/ 147/ 105 PCR- RFLP OR  Y402H associated with AMD 
81 
 
2012 56 TC= 2.22 (95% CI: 1.23-4.00)  
CC= 4.12 (95% CI: 1.96-8.65) 
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Table 2: Association studies between AMD and ARMS2 rs10490924 polymorphism 
ARMS2 (rs10490924) 
Study/ year Country/ 
Patient/ 
Controls 
Genotyping 
method 
Results  Conclusions 
Yang et al 2006 
65 
USA/ 442/ 309 Not specified OR  
TG= 1.35 (95% CI; 0.99, 1.86) 
TT=6.09 (95% CI; 3.27, 11.34) 
ARMS2 significantly associated 
with AMD 
Pulido et al 2007 
45  
USA/ 87 NVAMD/ 
232 
PCR-RFLP OR  
TG= 3.35 (95% CI= 1.91-5.90). 
TT= 7.75 (95% CI; 3.46-17.35).  
 
ARMS2 significantly associated 
with AMD 
Francis et al 
2007 72 
USA/ 333 (108 
GA, 205 CNV)/ 
171  
PCR 
followed by 
TGCE or 
direct 
sequencing 
OR= 4.671 (3.245, 6.722) ARMS2 significantly associated 
with AMD 
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Fisher et al 2007 
55 
 
Russia/ 155/ 151 Sequencing  The frequency of the risk allele was not 
significantly different between AMD cases 
(31.6%) and controls (28.5%) 
In late AMD, risk for the disease increased with 
TG OR=2.55 (95% CI 1.24-5.24) 
TT OR=3.47 (95% CI 1.01- 11.88) 
Contribution of ARMS2 to risk is 
weak and found only in late stage 
AMD 
 
Rivera et al 2005 
69 
Germany/ 1166/ 
922 
MALDI-
TOF 
TT= 7.6-fold increased risk  
OR= 57.6 (95% CI: 37.2, 89.0) for individuals 
homozygous for risk alleles at both CFH 
Y402H and LOC387715.  
ARMS2 significantly associated 
with AMD 
Xu et al 2008 
68 
China/ 121  
NVAMD/ 132  
PCR-RFLP 
and 
sequencing 
OR  
TG= 1.56 (95% CI; 0.80–3.03)  
TT= 5.45 (95% CI; 2.59–11.49)  
 
ARMS2 significantly associated 
with AMD 
Kaur et al 2008 
70  
India/ 250/ 250 Sequencing  Significant associations were found with the 
risk alleles of rs10490924 (T allele; P = 5.34 x 
10
-12
)  
ARMS2 significantly associated 
with AMD 
Soysal et al 2012 
56 
Turkey/ 147/ 105 PCR-RFLP OR 
TG= 1.88 (95% CI: 1.07 to 3.30) 
TT= 8.61 (95% CI: 3.55 to 20.87) 
 
ARMS2 significantly associated 
with AMD 
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Table 3: Association studies between AMD and HTRA1 rs11200638 polymorphism 
HTRA1 (rs11200638) 
Study/ year Country/ 
Patient/ 
Controls 
Genotyping method Results  Conclusions 
Yang et al 2006 
65 
USA/ 442/ 309 Not specified OR  
GA=1.86 (95% CI; 1.35, 2.56) 
AA= 6.56 (95% CI; 3.23,13.31) 
p = 1x l0 
-9
 
rs1l200638 significantly associated 
with AMD 
Xu et al 2008 
68 
China/ 121  
NVAMD/ 132  
PCR-RFLP and 
sequencing 
OR 
GA= 2.75 (95% CI; 1.34– 5.64),  
AA=7.90 (95% CI; 3.61–17.26)  
rs1l200638 significantly associated 
with AMD 
Francis et al 
2007 72 
USA/ 333 (108 
GA, 205 CNV)/ 
171  
PCR followed by TGCE 
or direct sequencing 
OR 3.973 (95% CI; 2.928, 5.390) rs1l200638 significantly associated 
with AMD 
Yang et al 2010  
66 
China (Han 
Chinese)/ 109 
NVAMD/ 150 
Taqman assay OR for GA and AA combined was 
2.02 (95% CI; 1.20-3.39) 
rs1l200638 significantly associated 
with AMD 
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Kaur et al 2008 
70  
India/ 250/ 250 Sequencing  Significant associations were found 
with the risk alleles of rs11200638 
(A allele; p = 4.32 x 10
-12
)  
rs1l200638 significantly associated 
with AMD 
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Table 4: PCR primers for genotyping the three SNPs  
 Forward (5'-3') Backward (5'-3') 
CFH rs1061170  63  TCA TTG TTA TGG TCC 
TTA GGA AA 
TTA GAA AGA CAT 
GAA CAT GCT AGG 
ARMS2 rs10490924 68 TAC CCA GGA CCG 
ATG GTA AC 
GAG GAA GGC TGA 
ATT GCC TA 
HTRA1 rs11200638 68 ATG CCA CCC ACA  
ACA ACT TT 
CGC GTC CTT CAA 
ACT AAT GG 
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Table 5: Restriction digestion reaction conditions 68 
Locus Enzyme Conditions 
CFH rs1061170 Tsp 509I 65˚C, buffer 1, for 3 hours 
ARMS2 rs10490924 Pvu III 37˚C, buffer 2,  for 3 hours  
HTRA1 rs11200638 Eag I 37˚C, buffer 3,  for 3 hours 
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Table 6: Characteristics of the study population  
 AMD patients 
(n=26) 
Controls 
(n=20) 
All subjects 
(n=46 ) 
p-value  
Age (mean ± 
SD) 
65 ± 8 years 60 ± 8 years 63 ± 8 years 0.079 
Sex 
Male 
Female  
 
17 (65.4%) 
9 (34.6%) 
 
9 (45%) 
11 (55%) 
 
26 
20 
0.279 
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Table 7: Results of restriction digestion for the three SNPs showing band 
distribution and size 
 Wild type homozygous Risk homozygous Heterozygous 
CFH 
rs1061170 
TT CC TC 
Two bands One band Three bands  
181+60bp 241bp 241+181+60bp 
ARMS2 
rs10490924 
GG TT TG 
Two bands One band Three bands 
259+190bp 449bp 449+259+190bp 
HTRA1 
rs11200638 
GG AA GA 
Two bands One band Three bands 
246+139bp 385bp 385+246+139bp 
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Table 8: Genotype and allele frequencies of patients and controls in CFH 
rs1061170 
Genotypes AMD cases 
(n=20) 
Controls 
(n=15) 
χ2 p-value OR 
(95%CI) 
CFH  
rs1061170 
Genotype 
       TT 
       TC 
        
       CC 
   CC + TC 
 
 
 
Allele 
frequency 
        C 
 
 
 
 
4 (20%) 
11 (55%) 
 
5 (25%) 
16 (80%)  
HW p=1.0 
 
 
 
 
0.53 +/-
0.075 
 
 
 
10(66.7%) 
5 (33.3%) 
 
0 
5 (33.3%) 
HW p=1.0 
 
 
 
 
0.17 +/-0.061 
 
 
 
 
4.82  
 
 
7.78 
 
 
 
 
 
9.43 
 
 
 
 
0.02811 
 
 
0.00529 
 
 
 
 
 
0.00214 
 
 
 
1.0 (ref) 
5.5 (1.145-
26.412) 
 
8 (1.726-
37.090) 
 
 
 
 
5.526 
(1.762-
17.336) 
HW: Hardy Weinberg Equilibrium, OR: Odds ratio, CI: Confidence interval 
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Table 9: Genotype and allele frequencies of patients and controls in ARMS2 
rs10490924 
Genotypes AMD cases 
(n=24) 
Controls 
(n=20) 
χ2 p-value OR 
(95%CI) 
ARMS2 
rs10490924   
Genotype 
       GG 
       TG 
       
 
       TT 
    TT+TG 
 
Allele 
frequency 
        T 
 
 
 
 
6 (25%) 
12 (50%) 
 
 
6 (25%) 
18 (75%) 
HW p=1.0 
 
 
0.50 +/-
0.072 
 
 
 
14 (70%) 
6 (30%) 
 
 
0 
6 (30%) 
HW p=1.0 
 
 
0.15 +/-0.051 
 
 
 
 
5.11 
 
 
 
8.91 
 
 
 
11.90 
 
 
 
 
0.02380 
 
 
 
0.00284 
 
 
 
0.00056 
 
 
 
1.0 (ref) 
4.667 
(1.187-
18.352) 
 
7 (1.852-
26.461) 
 
 
5.667 
(2.011-
15.969) 
HW: Hardy Weinberg Equilibrium, OR: Odds ratio, CI: Confidence interval 
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Table 10: Genotype and allele frequencies of patients and controls in HTRA1 
rs11200638 
Genotypes AMD cases 
(n=24) 
Controls 
(n=15) 
χ2 p-value OR 
(95%CI) 
HTRA1 
rs11200638 
Genotype 
       GG 
       GA 
       
 
       AA 
    AA+GA 
 
Allele 
frequency 
        A 
 
 
 
 
6 (25%) 
15 (62.5%) 
 
 
3 (12.5%) 
18 (75%) 
HW p=1.0 
 
 
0.44 +/-
0.061 
 
 
 
10 (66.7%) 
5 (33.3%) 
 
 
0 
5 (33.3%) 
HW p=0.403 
 
 
0.17 +/-0.061 
 
 
 
 
5.14 
 
 
 
6.62 
 
 
 
6.09 
 
 
 
 
0.02334 
 
 
 
0.01006 
 
 
 
0.01357 
 
 
 
1.0 (ref) 
5 (1.195-
20.922) 
 
 
6 (1.456-
24.733) 
 
 
3.889 
(1.273-
11.880) 
HW: Hardy Weinberg Equilibrium, OR: Odds ratio, CI: Confidence interval 
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Table 11: combination of genotypes of ARMS1 and HTRA1 in patients and 
controls 
   HTRA1 
   GG GA AA 
AMD cases ARMS1 GG 6 (27.3%) 0 0 
TG 0 11 (50%) 0 
TT 0 2 (9%) 3 (13.6%) 
Controls ARMS1 GG 10 (66.7%) 1 (6.7%) 0 
TG 0 4 (26.7%) 0 
TT 0 0 0 
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Table 12: Genotype and allele frequencies of patients and controls in carriers of 
the (GT+AG) ARMS2, HTRA1 combination  
Genotypes AMD cases 
(n=20) 
Controls 
(n=14) 
χ2 p-value OR (95%CI) 
HTRA1 
rs11200638 
Genotype 
    GG+GG 
    GA+TG 
       
 
    AA +TT 
     
 
 
Allele 
frequency 
        A+T 
 
 
 
 
6 (30%) 
11 (55%) 
 
 
3 (15%) 
 
HW p=1.0 
 
 
 
0.42 +/-
0.073 
 
 
 
10 (71.4%) 
4 (28.6%) 
 
 
0 
 
HW p=1.0 
 
 
 
0.14 +/-0.060 
 
 
 
 
4.01 
 
 
 
 
 
 
 
 
6.14 
 
 
 
 
0.04513 
 
 
 
 
 
 
 
 
0.01320 
 
 
 
1.0 (ref) 
4.583  
C.I.=[0.995-
21.119] 
 
 
 
 
 
4.435 
(1.296-
15.176) 
HW: Hardy Weinberg Equilibrium, OR: Odds ratio, CI: Confidence interval 
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Table 13: Independent laboratories conducting genetic testing for AMD 
Laboratories offering clinical testing Sequence analysis 
of the entire coding 
region 
Targeted 
mutational 
analysis 
Deletion/ 
duplication 
analysis 
Website 
Molecular Genetics Laboratory  
Salt Lake City, UT 
 
 ✓  http://www.aruplab.com/guides/ug/test
s/0051674.jsp 
Bay Area Genetic Laboratory  
Hamilton, Ontario, Canada 
 
 ✓  http://www.bagl.ca/ 
CeGaT GmbH  
Tuebingen, Germany 
 
✓   http://www.cegat.de/ 
Molecular Genetics  
Martinsried, Bayern, Germany 
 
 ✓  http://www.medizinische-genetik.de/ 
UCD DNA Diagnostic Laboratory  
Aurora, CO 
 
✓   http://www.ucdenver.edu/academics/c
olleges/medicalschool/programs/geneti
cs/Pages/DenverGenetics.aspx 
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Medical Genetics Unit  
Paterna, Comunidad Valenciana, Spain 
 
✓   https://www.sistemasgenomicos.com/
web_sg/webing/areas-biomedicina-
ugm.php 
Laboratory of Human Genetics  
Warsaw, Mazowieckie, Poland 
 
 ✓  http://nzoz.genomed.pl/index.php?str=
dim&lng=en 
Advanced Diagnostic Laboratories (ADx)  
Denver, CO 
 
 ✓  http://www.nationaljewish.org/professi
onals/clinical-services/diagnostics/adx/ 
Casey Eye Institute Molecular Diagnostic 
Laboratory  
Portland, OR 
 
✓   http://www.ohsu.edu/xd/health/service
s/casey-eye/diagnostic-services/cei-
diagnostics/index.cfm 
Molecular Diagnostics and BioBanking  
Marshfield, WI 
 
✓  ✓ http://www.preventiongenetics.com/  
Molecular Genetics Laboratory  
San Juan Capistrano, CA 
 
 ✓  http://www.questdiagnostics.com/hom
e.html 
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Sequenom Center for Molecular Medicine 
- Grand Rapids  
Grand Rapids, MI 
 
 ✓  http://www.sequenomcmm.com/ 
 
